Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04910568
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Daratumumab to Treat Active Lupus Nephritis
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT04868838
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Genmab
- Target Recruit Count
- 252
- Registration Number
- NCT04824794
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, New Zealand
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 100
- Registration Number
- NCT04782687
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
DARA RVD For High Risk SMM
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 61
- Registration Number
- NCT04775550
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 52
- Registration Number
- NCT04756401
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04722146
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 1
- Registration Number
- NCT04700176
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 20
- Registration Number
- NCT04667663
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪Galway University Hospital, Galway, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.